Warby Parker
WRBY
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$11.2m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$30.34
+44.0% in the quarter
Share price change by quarter
+1.7%Q3 ’24
+48.3%Q4 ’24
-24.7%Q1 ’25
+20.3%Q2 ’25
+25.8%Q3 ’25
-21.0%Q4 ’25
-3.3%Q1 ’26
+44.0%Q2 ’26
Managers holding it, by quarter
1Q4 ’23
1Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
3Q1 ’25
3Q2 ’25
3Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Who holds it
| Gardner Russo & Quinn | 0.0%$2.4m | Unchanged |
| First Eagle Investment Management | 0.0%$8.7m | Added +113% |
Directors buying and selling
How this works
| Bought or sold | ||||
|---|---|---|---|---|
| 1 Oct 2026 | Blumenthal Neil HarrisCo-Chief Executive Officer | ▼ Sold | 100,000 | $2.8m |
| 1 Oct 2026 | Raider Jeffrey JacobDirector | ▼ Sold | 15,000 | $416k |
About the company
- Sector
- Health care · Ophthalmic Goods
- Incorporated in
- Delaware
- Financial year ends
- 31 December
- Shares outstanding
- 113m at 9 Nov 2021
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$370m2019
$394m2020
$541m2021
$598m2022
$670m2023
$771m2024
$872m2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $872m | $1.6m |
| 2024 | $771m | −$20.4m |
| 2023 | $670m | −$63.2m |
| 2022 | $598m | −$110m |
| 2021 | $541m | −$144m |
| 2020 | $394m | −$55.9m |
| 2019 | $370m | $0k |